WilliamTCurryMD
Neurosurgery • Boston, MABrain & Spinal Tumor, Pituitary Surgery
Professor of Neurosurgery, Harvard Medical School Chief Medical Officer, Massachusetts General Hospital
Dr. Curry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Yaw 9 Brain Tumor Center Neuro Oncology
Boston, MA 02114Phone+1 617-726-3779Fax+1 617-724-8769- Is this information wrong?
Summary
- Dr. William Curry is a neurosurgeon in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital and Veterans Affairs Connecticut Healthcare System. He received his medical degree from Weill Cornell Medicine and has been in practice 20 years. He specializes in brain & spinal tumor and pituitary surgery and is experienced in neurosurgical oncology, skull base surgery, and neurosurgical trauma and critical care. He has more than 100 publications and over 500 citings.
Education & Training
Massachusetts General HospitalResidency, Neurological Surgery, 1998 - 2003- Massachusetts General HospitalInternship, Transitional Year, 1997 - 1998
Weill Cornell MedicineClass of 1997
Certifications & Licensure
MA State Medical License 2001 - 2024- American Board of Neurological Surgery Neurological Surgery
Awards, Honors, & Recognition
- Fellow (FAANS) American Association of Neurological Surgeons
Clinical Trials
- Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor Start of enrollment: 2008 Jun 01
- Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2013 May 01
- A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy Start of enrollment: 2015 May 01
- Join now to see all
Publications & Presentations
PubMed
- Radical surgical resection with molecular margins is associated with improved survival in IDH wildtype GBM.Elie Massaad, William J Smith, Joseph Bradley, Eric Esposito, Mihir Gupta, Evan Burns, Ryan Burns, José K Velarde, Inka K Berglar, Rajiv Gupta, Maria Martinez-Lage, Jo...> ;Neuro-Oncology. 2024 Apr 6
- Endoscopic endonasal approach for olfactory groove meningioma resection: Strategies and outcomes in a retrospective case series.Amy J Wang, Max Blanch, Christine K Lee, Pratik A Talati, Stacey T Gray, Benjamin S Bleier, George A Scangas, Eric H Holbrook, William T Curry> ;Journal of Clinical Neuroscience. 2024 Apr 1
- Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.Bryan D Choi, Elizabeth R Gerstner, Matthew J Frigault, Mark B Leick, Christopher W Mount, Leonora Balaj, Sarah Nikiforow, Bob S Carter, William T Curry, Kathleen Gall...> ;The New England Journal of Medicine. 2024 Apr 11
- Join now to see all
Journal Articles
- Sequestration of T Cells in Bone Marrow in the Setting of Glioblastoma and Other Intracranial TumorsPeter E Fecci, Cosette A Dechant, Robert L Martuza, Karolina Woroniecka, Brian V Nahed, James E Herndon, William T Curry, Aladine A Elsamadicy, John H Sampson, Michael..., Nature
Other
- Recently Viewed (1) Article Information Headings Figures References TrendMD Related Metrics PubMed Google ScholarWilliam Curry, MD, Journal of Neurosurgery
https://www.doximity.com/articles/43357e49-e243-4d19-822a-04fbedc5981a
UpToDate, Wolters Kluwer Health - 2013-02-19
Authored Content
- Recently Viewed (1) Article Information Headings Figures References TrendMD Related Metrics PubMed Google ScholarDecember 2018
- Histopathological Prognostic Factors of Recurrence Following Definitive Therapy for Atypical and Malignant Meningiomas RelatedApril 2018
- Histopathological Prognostic Factors of Recurrence Following Definitive Therapy for Atypical and Malignant Meningiomas RelatedApril 2018
- Histopathological Prognostic Factors of Recurrence Following Definitive Therapy for Atypical and Malignant Meningiomas RelatedApril 2018
- Join now to see all
Press Mentions
Miles for Mary Dinner to Be Held in Marblehead Nov. 2October 29th, 2015
NeuroBlast E-newsletter June 2014November 1st, 2014- The Survival Advantage: How the Intraoperative Neurophysiology Monitoring Unit at Massachusetts General Hospital Lowers Surgical Risk and Improves ProOctober 2nd, 2018
- Join now to see all
Professional Memberships
- Member
- Fellow
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
